Most recently, Mr Dro was chairman and CEO of Endoart, a medtech company developing telemetric driven implants for cardiac disease and obesity, which was sold to Allergan.
Mr Dro earned a Pharm D from University of Grenoble (France) and an MBA jointly from Ecole Superieure de Commerce de Lyon (France) and Cranfield School of Management (UK).
Michel Greco, chairman of GlycoVaxyn, said: “Philippe’s extensive experience working with emerging companies in strategic, business and commercial development capacities will prove extremely valuable to GlycoVaxyn.”